Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP4F2 | P78329 | 1/20 | 0.49 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.43 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.43 |
| ▸ | NAMPT | P43490 | 1/20 | 0.43 |
| ▸ | MMP9 | P14780 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | LIMK2 | P53671 | 1/20 | 0.42 |
| ▸ | HTR2C | P28335 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL925686 | 0.89 | CYP4F2 (0.56) | CYP4F2CYP4A11MAPTGAAALDH1A1 | |
| SCHEMBL21411396 | 0.86 | CYP4F2 (0.53) | CYP4F2CYP4A11MAPTGAAALDH1A1 | |
| SCHEMBL16661094 | 0.85 | ESR2 (0.45) | MAPTSMN1; SMN2SLC18A3SIGMAR1 | |
| SCHEMBL11674790 | 0.84 | RORC (0.52) | CYP4F2CYP4A11MAPTGAAALDH1A1 | |
| SCHEMBL11564250 | 0.84 | RORC (0.52) | CYP4F2CYP4A11MAPTGAAALDH1A1 | |
| SCHEMBL31263875 | 0.83 | HTR2C (0.54) | GAAALDH1A1SLC18A3SIGMAR1HTR2C | |
| Hydrochloric Acid SCHEMBL9409381 | 0.83 | HRH3 (0.44) | ALDH1A1SMN1; SMN2NAMPTHTR2C | |
| SCHEMBL3942448 | 0.83 | HTR2C (0.54) | GAAALDH1A1SLC18A3SIGMAR1HTR2C | |
| SCHEMBL31579906 | 0.82 | MMP9 (0.54) | CYP4F2CYP4A11MAPTGAAALDH1A1 | |
| SCHEMBL15054359 | 0.81 | SLC18A3 (0.53) | GAASLC18A3SIGMAR1NAMPTLIMK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2785690-B1 | PIPERIDINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | BOEHRINGER INGELHEIM INT (DE) | 2016-07-13 | — | — | EP | disclosed |
| US-8975235-B2 | Lysophosphatidic acid receptor antagonists | INTERMUNE, INC. (US) | 2015-03-10 | — | — | US | disclosed |
| US-8975235-B2 | Lysophosphatidic acid receptor antagonists | INTERMUNE, INC. (US) | 2015-03-10 | — | — | US | disclosed |
| EP-2785690-A1 | PIPERIDINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | Boehringer Ingelheim International GmbH (DE) | 2014-10-08 | — | — | EP | disclosed |
| US-8759528-B2 | Piperidine derivatives, pharmaceutical compositions and uses thereof | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-06-24 | — | — | US | disclosed |
| US-8759528-B2 | Piperidine derivatives, pharmaceutical compositions and uses thereof | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-06-24 | — | — | US | disclosed |
| US-8759528-B2 | Piperidine derivatives, pharmaceutical compositions and uses thereof | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-06-24 | — | — | US | disclosed |
| US-20130143876-A1 | New piperidine derivatives, pharmaceutical compositions and uses thereof | ROTH GERALD JUERGEN (DE) | 2013-06-06 | — | — | US | disclosed |
| WO-2013079668-A1 | PIPERIDINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-06-06 | — | — | WO | disclosed |
| US-20130143876-A1 | New piperidine derivatives, pharmaceutical compositions and uses thereof | ROTH GERALD JUERGEN (DE) | 2013-06-06 | — | — | US | disclosed |
| WO-2013079668-A1 | PIPERIDINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-06-06 | — | — | WO | disclosed |
| US-20130143876-A1 | New piperidine derivatives, pharmaceutical compositions and uses thereof | ROTH GERALD JUERGEN (DE) | 2013-06-06 | — | — | US | disclosed |
| US-20130072449-A1 | LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONISTS | INTERMUNE, INC. (US) | 2013-03-21 | — | — | US | disclosed |
| US-20130072449-A1 | LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONISTS | INTERMUNE, INC. (US) | 2013-03-21 | — | — | US | disclosed |
| WO-2013025733-A1 | LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONISTS | INTERMUNE, INC. (US) | 2013-02-21 | — | — | WO | disclosed |
| US-20040092737-A1 | Benzopiperidine derivatives | EISAI CO., LTD. | 2004-05-13 | — | — | US | disclosed |
| US-6518423-B1 | These compounds are useful as drugs efficacious in the prevention and treatment of these various inflammatory diseases and immunologic diseases, such as rheumatoid arthritis, atopic dermatitis, psoriasis, asthma, and | EISAI CO., LTD. (JP) | 2003-02-11 | — | — | US | disclosed |
| EP-0934941-A1 | BENZOPIPERIDINE DERIVATIVES | Eisai Co., Ltd. (JP) | 1999-08-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040092737-A1 | Benzopiperidine derivatives | HLA-DRB1, HRH1, HRH2 | CYP4F2 264/4885CYP4A11 131/4885MAPT 1257/4885 |
| US-20130143876-A1 | New piperidine derivatives, pharmaceutical compositions and uses thereof | P2RX5, PIR, P2RX4 | CYP4F2 2257/4885CYP4A11 1993/4885MAPT 2067/4885 |
| US-20130072449-A1 | LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONISTS | LPAR1, LPAR2, LPAR5 | CYP4F2 4236/4885CYP4A11 2910/4885MAPT 4564/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.